Evolution of stimulants to treat ADHD: Transdermal methylphenidate

Human Psychopharmacology

Volumn 24, Issue 1, 2009, Pages 1-17

  Patrick, Kennerly S ^a   Straughn, Arthur B ^b   Perkins, Jeb S ^a   González, Mario A ^c  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c P Kinetics International Inc   (United States)

Author keywords

Amphetamine; Enantiomer; Methylphenidate; Pharmacodynamics; Pharmacokinetics; Transdermal

Indexed keywords

AMPHETAMINE; ATOMOXETINE; BIPHENTIN; DEXAMPHETAMINE; DEXMETHYLPHENIDATE; GENERIC DRUG; LIQUADD; LISDEXAMFETAMINE; METHYLPHENIDATE; PLACEBO; UNCLASSIFIED DRUG; CENTRAL STIMULANT AGENT;

ANOREXIA; AREA UNDER THE CURVE; ATTENTION DEFICIT DISORDER; CLINICAL TRIAL; CONTACT DERMATITIS; CONTROLLED RELEASE FORMULATION; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG ABUSE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERANCE; ENANTIOSELECTIVITY; HALF LIFE TIME; HUMAN; INSOMNIA; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION; WEIGHT REDUCTION; DELAYED RELEASE FORMULATION; INTRADERMAL DRUG ADMINISTRATION; SKIN ABSORPTION; STEREOISOMERISM; TIME;

ADMINISTRATION, CUTANEOUS; AMPHETAMINE; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CLINICAL TRIALS AS TOPIC; DELAYED-ACTION PREPARATIONS; DERMATITIS, CONTACT; HUMANS; METHYLPHENIDATE; SKIN ABSORPTION; STEREOISOMERISM; TIME FACTORS;

EID: 60549106486     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.992     Document Type: Review

References (166)

1. Abdou HM, Hanna S, Muhammad N. 2000. Dissolution. In Remington: The Science and Practice of Pharmacy, 20th edn, Gennado AR (ed.). Lippincott Williams & Wilkins: Baltimore; 654-666.
2. Aboul-Enein HY, Wainer IW. 1997. The Impact of Stereochemisrty on Drug Development and Use. John Wiley & Sons: New York.
3. Ahmed S, Imai T, Yoshigae Y, Otagiri M. 1997. Stereospecific activity and nature of metabolizing esterases for propranolol in hairless mouse skin, liver and plasma. Life Sci 61: 1879-1887.
4. Anderson VR, Scott LJ. 2006. Methylphenidate transdermal system. Drugs 66: 1117-1126.
5. Andreason PJ. 2005. Methylphenidate transdermal patch. www.fda.gov/ ohrms/dockets/ac/05/slides/2005-4195S101FDA-Andreason.ppt
6. Anonymous. 2006. Transdermal methylphenidate (Daytrana) for ADHD. Med Lett 48(1237): 49-51.
7. Aoyama T, Sasaki T, Kotaki J. 1994. Pharmacokinetics and pharmacodynamics of (+)-threo-methylphenidate enantiomer in patients with hypersomnia. Clin Pharmacol Ther 55: 270-276.
8. Arnold LE, Huestis RD, Wemmer D, Smeltzer DJ. 1978. Differential effect of amphetamine optical isomers on Bender Gestalt performance of the minimally brain dysfunctional. J Learn Disabil 11: 14-19.
9. Arnold LE, Lindsey RL, Conners CK, et al. 2004. A double-blind, placebo-controlled withdrawal trial of dexmethylphenidate hydrochloride in children with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 14: 542-554.
10. Arnold LE, Wender PH, McCloskey K, Snyder PH. 1972. Levoamphetamine and dextroamphetamine: comparative efficacy in the hyperkinetic syndrome. Arch Gen Psychiatry 27: 816-822.
11. Baldessarini B, Cambell A. 2001. Method of dopamine inhibition using l-methylphenidate. US Patent 6,221,883.
12. Barrett SP, Darredeau C, Bordy LE, Pihl RO. 2005. Charateristics of methylphenidate misuse in a university student sample. Can J Psychiatry 50: 457-461.
13. Barrett SP, Pihl RO. 2002. Oral methylphenidate-alcohol co-abuse. J Clin Psychopharmacol 22: 633-634.
14. Bass DM, Prevo M, Waxman DS. 2002. Gastrointestinal safety of an extended-release, nondeformable, oral dosage form (OROS): a retrospective study. Drug Safety 25: 1021-1024.
15. Berridge CW, Waterhouse BD. 2003. The locus coeruleus-noradrenergic system: modulation of behavioral state and state-dependent cognitive processes. Brain Res Rev 42: 33-84.
16. Birmaher B, Greenhill LL, Cooper TB, Fried J, Maminski B. 1989. Sustained release methylphenidate: pharmacokinetic studies in ADDH males. J Am Acad Child Adolesc Psychiatry 28: 768-772.
17. Blick SKA, Keating GM. 2007. Lisdexamfetamine. Pediatr Drugs 9: 129-135.
18. Block LH. 2000. Medicated topicals. In Remington: The Practice and Science of Pharmacy, 20th edn, Gennaro AR (ed.). Lippincott Williams & Wilkins: Baltimore MD; 836-857.
19. 1B receptor-mediated serotonergic modulation of methylphenidate-induced lcomotor activation in rats. Neuropsychopharmacology 33: 619-626.
20. Boswell MV. 1992. Fentanyl transdermal system overdose secondary to cutaneous hyperthemlia. Anesth Analg 77: 390-391.
21. Bradley C. 1937. Behavior of children receiving benzedrine. Am J Psychiatry 94: 577-585.
22. Bradley C. 1950. Benzedrine and Dexedrine in the treatment of children's behavior disorders. Pediatrics 5: 24-36.
23. Brown GL, Ebert MH, Mikkelsen EJ, Hunt RD. 1980. Behavioral and motor activity response in hyperactive children and plasma amphetamine levels following a sustained release preparation. J Am Acad Child Psychiatry 19: 225-239.
24. Bruno KJ, Hess EJ. 2006. The α2c-adrenergic receptor mediates hyperactivity of coloboma mice, a model of attention deficit hyperactivity disorder. Neurobiol Dis 23: 679-688.
25. Cefali EA, Banfield CR, González MA, Wagner JG. 1993. In vivo determination of zero-order absorption from a transdermal glycerol trinitrate system. Eur J Pharm Biopharm 39: 140-143.
26. Chan YP, Swanson JM, Soldi SS, Thiessen JJ, Macleod SM, Logan W. 1983. Methylphenidate hydrochloride given with or before breakfast: II. Effect on plasma concentrations of methylphenidate and ritalinic acid. Pediatrics 72: 56-59.
27. Concerta. 2006. Janssen-Ortho. Product monograph, 25 July; No: 106348. Confino-Cohen R, Goldberg A. 2005. Sussessful desensitization of methylphenidate-induced rash. J Child Adolesc Psychopharmacol 15: 703-705.
28. Darredeau C, Barrett SF, Jardin B, Pihl RO. 2007. Patterns and predictors of medication compliance, diversion, and misuse in adult prescribed methylphenidate users. Hum Psychophaharmacol 22: 529-536.
29. Davidson EJ, Craig F. 2000. Treatment of convulsive states. US Patent 7384959.
30. Davids E, Zhang K, Tarazi FI, Baldessarini RJ. 2002. Stereoselective effects of methylphenidate on motor hyperactivity in juvenile rats induced by neonatal 6-hydroxydopamine lesioning. Psychopharmacology 160: 92-98.
31. DAWN: Drug Abuse Warning Network. 2003. Annual emergency department data. DHHS. Substance Abuse and Mental Health Services Administration.
32. Ding YS, Fowler JS, Volkow ND. 2002. Is the 1-threo enantiomer of methylphenidate (Ritalin) inactive in the brain when given orally? [abstr]. Am Col Neuropsychopharmacol 8-12: 255.
33. Ding YS, Gatley SJ, Thanos PK, et al. 2004. Brain kinetics of methylphenidate (Ritalin) enantiomers after oral administration. Synapse 53: 168-175.
34. Dulean MK. 1990. Using psychostimulants to treat behavioral disorders of children and adolescents. J Child Adoles Psychopharmacol 1: 7-20.
35. DuPont RL, Buched RH, Wilford BB, Coleman JJ. 2007. School-based administration of ADHD drugs decline, along with diversion, theft, and misuse. J Sch Nurs 23: 349-352.
36. Eckerman DA, Moy SS, Perkins AN, Patrick KS, Breese GR. 1991. Enantioselective behavioral effects of methylphenidate in rats. Pharmacol Biochem Behav 40: 875-880.
37. Faraj BA, Israili ZH, Perel JM, et al. 1974. Metabolism and disposition of methylphenidate- 14C in man and animals. J Exper Pharmacol Ther 191: 535-547.
38. Faraone SV, Giefer EE. 2007. Long-term effects of methylphenidate transdermal delivery system treatment of ADHD on growth. J Am Acad Adolesc Psychiatry 46: 1138-1147.
39. Findling R, Lopez FA. 2005. The effects of transdermal methylphenidate with reference to Concerta in ADHD. Sci Proc Am Acad Child Adolesc Psychiatry 32: 123.
40. Findling RL, Bukstein OG, Melmed RD, et al. 2008. A randmnized, doubleblind, plascebo-controlled, parallel-group study of methylphenidate transdermal system in pediatric patientswith attention-deficit/hyperactivity disorder. J Clin Psychiatre 69: 149-159.
41. Froimovitz M, Gu Y, Dakin LA, et al. 2007. Slow-onset, long-duration, alkyl analogues of methylphenidate with selectivity for the dopamine transporter. J Med Chem 50: 219-232.
42. Froimowitz M, Patrick K, Cody V. 1995. Conformational analysis of methylphenidate aud its structural relationship to other dopamine reuptake blockers such as CFT. Pharm Res 12: 1430-1434.
43. Frolich M, Giannotti A, Modell JH. 2001. Opioid overdose in a patient using a fentanyl patch during treatment with a warming blanket. Anesth Analg 93: 647-648.
44. Glaser PEA, Thomas TC, Joyce BM, Castellanos FX, Gerhardt GA. 2005. Differential effects of amphetamine isomers on dopamine release in the rat striatum and nucleus accumbens. Psychopharmacology 178: 250-258.
45. Glaze SA, Robertson DW, Wise LD. 2002. Attention deficit-hyperactivity disorder: pathophysiology and design of new treatments. Annu Rep Med Chem 37: 11-20.
46. Gonzalez MA, Pentikis HS, Anden N, et al. 2002. Methylphenidate bioavailability from two extended-release formulations. Inter J Clin Pharmacol Ther 40: 175-184.
47. Goyer PF, Davies GC, Rapoport JL. 1979. Abuse of prescription stimulant medication by a 13-year-old hyperactive boy. J Am Acad Child Psychiatry 18: 170-175.
48. Gozal D, Molfeses DL. 2005. Attention Deficit Hyperactivity Disorder: From Genes to Patients. Humana Press: Totowa, NJ.
49. Greenhill LL. 1992. Pharmacologic treatment of attention deficit hyperactivity disorder. Psychiatr Clin North Am 15: 1-27.
50. Gutstein HB, Akil H. 2006. Opioid analgesics. In Goodman and Gilman's the Pharmacological Basis of Therpeutics, 11th edn, Branton LL, Lazo JS, Parker KL (eds). McGraw-Hill: New York; 547-590.
51. Haessler F, Tracik F, Stammer H, Klatt J. 2008. A pharmacokinetic study of two modified-release methylphenidate formulations under different food conditions in healthy volunteers. Int J Clin Pharmacol Ther 46: 466-476.
52. Heal DJ, Pierce DM. 2006. Methylphenidate and its isomers: their role in the treatment of attention-deficit hyperactivity disorder using transdermal delivery system. CNS Drugs 20: 713-734.
53. Heil SH, Holmes HW, Bickel WK, et al. 2002. Comparison of the subjective, physiological, and psychotor effects of atomexetine and methylphenidate in light drug abusers. Drug Alcohol Depend 67: 149-156.
54. Hitri A, Hurd Y, Wyatt RJ, Deutsch SI. 1994. Molecular, functional and biochemical characteristics of the dopamine transporter: regional differences and clinical relevance. Clin Neuropharmacol 17: 1-22.
55. Hull W. 2002. Heat-enhanced drug delivery: a survey paper. J Appl Res Clin Exp Ther 2: 69-76.
56. Hurwitz J. 2001. Swallowing-tablets and capsules: a guide for parents, care givers, and children 4 years and up. Duke Pediatric Clinical Research Program, Room 1080. Duke South Hospital, Durham, NC 27710.
57. Jaffe SL, 1991. Intranasal abuse of prescribed methylphenidate by an alcohol and drug abusing adolescent with ADHD. J Am Acad J Child Adolesc Psychiatry 30: 773-775.
58. Jam, U, Hechtman L, Weiss M, et al. 2007. Efficacy of a novel biphasic controlled-release methylphenidate formula in adults with attention-deficit/hyperactivity disorder: results of a double-blind, placebo-controlled crossover study. J Clin Psychiatry 68: 268-277.
59. Janowsky DS, Davis JM. 1976. Methylphenidate, dextroamphetamine and levamfetamine. Arch Gen Psychiatry 33: 304-308.
60. Jonkman LM, Verbaten MN, Deboer D, et al. 1994. Differences in plasma concentrations of the D- and L-threo methylphenidate enantiomers in responding and non-responding children with attention-deficit hyperactivity disorder. Psychiatry Res 78: 115-118.
61. Kagan L, Hoffman A. 2008. Systems for region selective drug delivery in the gastrointestinal tract: biopharmaceutical considerations. Expert Opin Drug Deliv 5: 681-692.
62. Kahlig KM, Galli A. 2003. Regulation of dopamine transporter function and plasma membrane expression by dopamine, amphetamine, and cocaine. Eur J Pharmacol 479: 153-158.
63. Karch SB. 1996. The Pathology of Drug Abuse, 2nd edn. CRC Press: Boca Raton; 199-240.
64. Khetani V, Faleck H. 2004. Method of diminishing co-abuse potential. US Patent App. 20050239830.
65. Klein-Schwartz W. 2002. Abuse and toxicity of methylphenidate. Curr Opin Pediatr 14: 219-223.
66. Kollins SH, Rush CR, Pazzaglia PJ, Ali JA. 1998. Comparison of acute behavioral effects of sustained-release and immediate-release methylphenidate. Exp Clin Psychopharmacol 6: 367-374.
67. Kowalik S, Minami H, Silva RR. 2007. Critical assessment of the methylphenidate transdermal system. Drugs Today 43: 515-527.
68. Kuczenski R, Segal DS. 2001. Locomotor effects of acute and repeated threshold doses of amphephetamine and methylphenidate: Relative roles of dopamine and norepinephrine. J Pharmacol Exper Ther 296: 876-483.
69. Lakoski JM, Galloway MP, White FJ. 1992. Cocaine Pharmacology, Physiology and Clinical Strategies, CRC Press: Boca Raton.
70. Lee L, Kepple J, Wang Y, et al. 2003. Bioavailability of modified-release methylphenidate: influence of high-fat breakfast when administered intact and when capsule content sprinkled on applesauce. Biopharm Drug Dispos 24: 233-243.
71. LeVasseur NL, Zhu H-J, Markowitz JS, DeVane CL, Patrick KS. 2008. Enantiospecific gas chromatographic-mass spectrometric analysis of urinary methylphenidate: implications for phenotyping. J Chromatogr B 862: 140-149.
72. Levine B, Caplan YH, Kauffman G. 1986. Fatality resulting from methylphenidate overdose. J Anal Toxicol 10: 209-210.
73. Lisska M, Rivkees SA. 2003. Dailey methylphenidate use slows the growth of children: a community based study. J Pediatr Endocrinol Metab 16: 711-718.
74. Llana ME, Crismon ML. 1999. Methylphenidate: increased abuse or appropriate use? J Am Pharm Assoc 39: 526-530.
75. Mantelle J, Dixon TA. 2001. Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate. US Patent 6,210,705 B1.
76. Markowitz JS, DeVane CL, Pestreich LK, Patrick KS, Muniz R. 2006. Comprehensive in vitro screening of d, 1- and dl-methylphenidate: an exploratory study. J Child Adolesc Psychopharmacol 16: 687-698.
77. Markowitz JS, Patrick KS. 2008. Differential pharmacokinetics and pharmacodynamics of methylphenidate enantiomers: does chirality matter? J Clin Psychopharmacol 28: S54-S61.
78. Markowitz JS, Straughn AB, Patrick KS. 2003a. Advances in the pharmacotherapy of attention - deficit hyperactivity disorder. Pharmacotherapy 23: 1281-1299.
79. Markowitz IS, Straughn AB, Patrick KS, et al. 2003b. Pharmacokinetics of two modified-release methylphenidate formulations in normal volunteers: Ritalin LA versus Concerta. Clin Pharmacokinet 42: 393-401.
80. Mays DA, Findling R. 2005. Methylphenidate transdermal system. J Am Acad Child Adolesc Psychiatry 44: 1223.
81. McConnell EL, Fadda HM, Basit AW. 2008. Gut instincts: explorations in intestinal physiology and drug delivery. Int J Pharm in press. Available online 20 May 2008, DOI: 10.1016/j.ipharm.2008.05.012
82. McDermott C. 2006. FDA warns consumers not to use Triaminic vapor patch. FDA News, 19 June, P06-P82.
83. McDougall SA, Collins RL, Karper PE. 1999. Effects of repeated methylphenidate treatment in the young rat: sensitization Of both locomotor. activity and stereotyped sniffing. Exp Clin Psychopharmacol 7: 208-218.
84. McGough JJ, Wigal SB, Abikoff H, Turnbow JM, Posner K, Moon E. 2006. A randomized, double-blind, placebo-controlled, laboratory classroom assessment of methylphenidate transdermal system in children with ADHD. J Attent Disord 9: 476-485.
85. McIntyre MB, Firemark HM, Cho AK, Cho AK, Bodner L, Gomez M. 1981. Computer analyzed EEG in amphetamine-response hyperactive children. Psychiatry Res 4: 189-198.
86. Meyer MC, Straughn AB, Jarvi EJ, et al. 2000. Bioequivalence of methylphenidate immediate-release tablets using a replicated study design. Pharmaceut Res 17: 381-384.
87. Midha KK, Teicher M, Kumar V. 2002. Method of treating depression using 1-threo-methylphenidate. US Patent 6,395,752.
88. Modi NB, Lindemulder G, Gupta SK. 2000. Single-and multiple-dose pharmacokinetics of oral once-a-day osmotic controlled-release OROS™ (methylphenidate HCl) formulation. J Clin Pharmacol 40: 379-388.
89. MTA Cooperative Group. 2004. National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: changes in effectiveness and growth after the end of treatment. Pediatrics 113: 762-769.
90. Noonan PK, González. MA. 1989. Pharmacokinetics and the variability of percutaneous absorption. J Toxicol Cutaneous Ocul Toxicol 8: 511-516.
91. Novak SP, Kroutil LA, Williams RL, Van Brunt DL. 2007 The nonmedical use of prescription ADHD medications: results from a national Internet panel. Subst Abuse Treat Prevent Policy 2: 1-17.
92. Noven/Shire. 2005a. Pharmacokinetics/pharmacodynamics summary NDA 21-514. 24 October: 1-43. http://fda.gov/dhrms/dockets/ac/o5/briefing/ 2005-4195-B101 02-Noven-Appendix-1.pdf [accessed 3 May 2007].
93. Noven/Shire. 2005b. Methylphenidate transdermal system NDA 21-514. FDA Psychopharmacologic Drugs Advisory Committee Briefing Document. December: 1-30.
94. Oades RD, Sadile, AG, Sagvolden T, et al. 2005. The control of responsiveness in ADHD by catecholamines: evidence for dopaminergic, noradrenergic and interactive roles. Dev Sci 8: 122-131.
95. Okie S. 2006. ADHD in adults. N Engl J Med 354: 2637-2641.
96. Pappinen S, Urtti A. 2006. Microemulsions in topical drug delivery. In Percutaneous Penetration Enhancers, 2nd edn, Smith EW, Mailbach HI (eds). CRC: New York; 109-116.
97. Parasrampuria DA, Schoedel KA, Gu J, Ciccone P, Silber SA, Sellers EM. 2007a. Assessment of pharmacokinetics and pharmacodynamic effects related to abuse potential of a unique oral osmotic-controlled extended-release methylphenidate formulation in humans. J Clin Pharamcol 47: 1476-1488.
98. Parasrampuria DA, Schoedel KA, Schuller R, et al. 2007b. Do formulation differences alter abuse liability of methylphenidate?: a placebo-controlled, randomized, double-blind, crossover study in recreational drug users. J Clin Psychopharmacol 27: 459-467.
99. Patrick KS. 2006a. Dexmethylphenidate extended-release; guest commentary. Drugs 66: 669-670.
100. Patrick KS, Caldwell RW, Ferris RM, Breese GR. 1987. Pharmacology of the enantiomers of threo-methylphenidate. J Pharmacol Exp Ther 241: 152-158.
101. Patrick KS, Kilts CD, Breese GR. 1981. Synthesis and pharmacology of hydroxylated metabolites of methylphenidate. J Med Chem 29: 1237-1240.
102. Patrick KS, Gonzalez MA, Straughn AB, Markowitz JS. 2005a. New methylphenidate formulations for the treatment of attentiondeficit/ hyperactivitydisorder. Exp Opin Drug Deliv 2: 121-143.
103. Patrick KS, Markowitz JS. 1997. Methylphenidate, amphetamine enantiomers and pemoline in the treatment of attention-deficit hyperactivity disorder. Human Psychopharmacol 12: 527-546.
104. Patrick KS, Straughn AB, Jarvi EJ, Meyer MC. 1989. The absorption of sustained-release methylphenidate formulations compared to an immediate-release formulation. Biopharm Drug Dispos 10: 165-171.
105. Patrick KS, Straughn AB, Minhinnett RR, et al. 2007. Influence of ethanol and gender on methylphenidate pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 81: 346-353.
106. Patrick KS, Williard RL, VanWert AL, Dowd JJ, Oatis JE, Jr, Middaugh LD. 2005b. Synthesis and pharmacology of ethylphenidate enantiomers: the human transesterification metabolite of methylphenidate and ethanol. J Med Chem 48: 2876-2881.
107. Pelham WE, Burrows-MacLean L, Gnagy EM, et al. 2005a. Transdermal methylphenidate, behavioral, and combined treatment for children with ADH. Exper Clin Psychopharmacol 13: 111-126.
108. Pelham WE, Greenslade KE, Vodde-Hamilton M, et al. 1990. Relative efficacy of long-acting stimulants on children with attention deficit-hyperactivity disorder: a comparison of standard methylphenidate, sustained-release methylphenidate, sustained-release dextroamphetamine, and pemoline. Pediatrics 86: 226-237.
109. Pelham WE, Manos MJ, Essell CE, et al. 2005b. A dose-ranging study of a methylphenidate transdermal system in children with ADHD. J Am Acad Child Adolesc Psychiatry 44: 522-529.
110. Pelham WE, Stuges J, Hoza J, et al. 1987. Sustained release and standard methylphenidate effects on cognitive and social behavior in children with attention deficit disorder. Pediatrics 80: 491-501.
111. Penberthy JK, Cox D, Breton M, et al. 2005. Calibration of ADHD assessments across studies: a meta-analysis tool. Appl Psychophysiol Biofeedback 30: 31-51.
112. Pentikis HS, Simmons RD, Benedict MF, Hatch SJ. 2002. Methylphenidate bioavailability in adults when an extended-release mutiparticulate formulation is administered on food or as an intact capsule. J Am Acad Child Adolesc Psychiatry 41: 443-449.
113. Perrin J, Erenberg G, LaCamera R, et al. 1996. Medication for children with attentional disorders. Pediatrics 98: 301-304.
114. Pierce DM, Dixon C, Wigal S, McGough J. 2005. Pharmacokineties of methylphenidate transdermal system in children with ADHD. 52nd Sci Proc Am Acad Child Adolesc Psychiatry, 131: B43.
115. Pierce D, Dixon CM, Wigal SB, McGough JJ. 2008. Pharmacokinetics of methylphenidate transdermal system (MTS): Results from a laboratory classroom study. J Child Adolesc Psychopharmacol 18: 355-364.
116. Pleuvry BJ. 2005. Hystertesis in drug response. Anesth Inten Care Med 6: 286-287.
117. Popper CW. 1994. The story of four salts. J Child Adolesc Psychiatry 4: 217-223.
118. Prashad M. 2001. Approaches to the preparation of enantiomerically pure 2R,2′R)-(+)-tireo-methylphenidate hydrochloride. Adv Synth Catal 343: 379-392.
119. Quinn D, Bode T, Reiz JL, Donnelly GAE, Darke AC. 2007. Single-dose pharmacokinetics of multilayer-release methylphenidate and immediate-release methylphenidate in children with attention-deficit/ hyperactivity disorder. J Clin Pharmacol 47: 760-766.
120. Quinn DMP. 2000. Methylphenidate: the role of the d-isomer. In Ritalin: Theory and Practice, 2nd edn, Liebert Pub: New York; 369-374.
121. Quinn D, Wigal S, Swanson J, et al. 2004. Comparative pharmacodynamics and plasma concentrations of d-threo-methylphenidate hydrochloride after single doses of d-threo-methylphenidate and dl-threo-methylphenidate hydrochloride in a double-blind, placebo-controlled, crossover laboratory school study in, children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 43: 1422-1429.
122. Rappley MD. 2005. Attention deficit-hyperactivity disorder. N Engl J Med 352: 165-173.
123. Reiz JL, Donnelly GAE, Michalko K. 2008. Comparative bioavailability of single-dose methylphenidate from a multilayer-release bead formulation and an osomotic system: a two-way crossover study in health young adults. Clin Ther 30: 59-69.
124. Robinson DM, Keating GM. 2006. Dexmethylphenidate extended-release. Drugs 66: 661-668.
125. Rometsch R. 1958. Process for conversion of streoisomers, US Patent 2,838,519.
126. Rouhi AM. 2003. Chirality at work. Chem Eng News May 5: 56-61.
127. Scarman EJ, Erdman AR, Cobaugh DJ, et al. 2007. Methylphenidate poisoning: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol 45: 737-752.
128. Schachar R, Ickowitz A, Crosbie J, et al. 2008. Cognitive and behavioral effects of multilayer-release methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder. J Child Adoles Psychopharmacol 18: 11-24.
129. Scheffler RM, Hinshaw SP, Modrek S, Levine P. 2007. The global market for ADHD medications. Health Trends 26: 450-457.
130. Shafi'ee A, Hite G. 1969. Stereochemical studies on medicinal agents. IV. Conformational analysis of ephedrine isomers and related compounds. J Med Chem 10: 1057-1063.
131. Shire Pharmaceuticals Ireland Limited. 2006. Daytrana prescribing information. Rev 04/06.
132. Shlomi D, Shitrit D, Bendayan D, Sahar G, Shechtman Y, Kamer MR. 2008. Successful lung transplantation for talcosis secondary to intravenous abuse of oral drug. Int J Chron Obstruct Pulmon Dis 3: 327-330.
133. Shore PA, Brodie BB, Hogben CA. 1957. The gastric secretion of drugs: a pH partion hypothesis. J Pharmacol Exp Ther 119: 361-369.
134. Silva RR. 2006. Methylphenidate transdermal system in attention-deficit hyperactivity disorder. Drugs 66: 1127-1128.
135. Silva R, Muniz R, McCague K, Childress A, Brams M, Mao A. 2008. Treatment of children with attention-deficit/hyperactivity disorder: results of a randomized, multicenter, double-blind, crossover study of extended-release dexmethylphenidate and d,l-methylphenidate and and placebo in a laboratory classroom setting. Psychopharmacol Bull 41: 19-33.
136. Solanto MV. 1998. Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration. Behav Brain Res 94: 127-152.
137. Spencer TJ, Biederman J, Ciccone PE, et al. 2006. PET study examining pharmacokinetics, detection and likeability, and dopamine transporter receptor occupancy of short- and long-acting oral methylphenidate. Am J Psychiatry 163: 387-395.
138. Srinivas NR, Barbhaiya RH, Midha KK. 2001. Enantiomeric drug development: issues, considerations, and regulatory requirements. J Pharm Sci 90: 1205-1215.
139. Srinivas NR, Hubbard JW, Quinn D, Midha KK. 1992. Enantioselective pharmacokinetics and pharmacodynamics of dl-threo-methylphenidate in children with attention deficit hyperactivity disorder. Clin Pharmacol Ther 52: 561-568.
140. Stein MA, Blondis TA, Schnitzler ER, et al. 1996. Methylphenidate dosing twice daily versus three times daily. Pediatrics 98: 748-756.
141. Stein MA, McGough JJ. 2008. The pharamcogenomic ers: promise for personalizing attention deficit hyperactivity disorder therapy. Child Adolesc Psychiatr Clin N Am 17: 475-490.
142. Swanson J, Gupta S, Guinta D, et al. 1999. Acute tolerance to methylphenidate in the treatment of attention deficit disorder in children. Clin Pharmacol Ther 66: 295-305.
143. Swanson J, Gupta S, Lam A, et al. 2003. Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 60: 204-211.
144. Swanson JM, Lerner M, Wigal T, et al. 2002. The use of laboratory school protocol to evaluate concepts about efficacy and side effects of new formulations of stimulant medications. J Attent Disord 6: S73-88.
145. Swanson JM, Volkow ND. 2002. Pharmacokinetic and pharmacodynamic properties of stimulants: implications for design of new treatments for ADHD. Behav Brain Res 130: 73-78.
146. Szporny L, Gorog P. 1961. Investigations into the correlations between monoamine oxidase inhibition and other effects due to methylphenidate and its stereoisomers. Biochem Pharmacol 8: 263-268.
147. Teicher MH, Polcari A, Foley M, et al. 2006. Methylphenidate blood levels and therapeutic response in children with attention-deficit hyperactivity disorder I. Effects of different dosing regimens. J Child Adolesc Psychopharmacol 16: 416-431.
148. Teo SK, Stirling DI, Thomas SD, Hoberman AM, Christian MS, Khetani VD. 2002. The perinatal and neonatal toxicity of D-methylphenidate and d,l-methylphenidate in rats. Reprod Toxicol 16: 353-366.
149. Teo SK, Stirling DI, Hoberman AM, Christian MS, Thomas SD, Khetani VD. 2003b. D-methylphenidate and D,L-methylphenidate are not developmental toxicants in rats and rabbits. Birth Defects Res 68: 162-171.
150. Teo SK, Stirling DI, Thomas SD, Khetani VD. 2003a. Neurobehavioral effects of racemic threo-methylphenidate and its d and l enantiomers in rats. Pharmacol Biochem Behav 74: 747-754.
151. Tuerck D, Wang Y, Maboudian M, et al. 2007. Similar bioavailability of dexmethylphenidate extended (bimodal) release, dexmethylphenidate immediate release and racemic extended (bimodal) release formulations in man. Int J Clin Pharmacol Ther 45: 662-668.
152. Vasiloff N, Cohen D, Dillon JB. 1965. Effective treatment of hiccup with intravenous methylphenidate. Can Anaesth Soc J 12: 306-310.
153. Vastag B. 2001. Pay attention: Ritalin acts much like cocaine. JAMA 286: 296-296.
154. Vetter VL, Elia J, Erickson C, et al. 2008. Cardiovascular monitoring of children and adolescents with heart disease receiving stimulant drugs. Circulation 117: 2407-2423.
155. Volkow ND, Swanson JM. 2003. Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD. Am J Psychiatry 160: 1909-1918.
156. Volkow ND, Wang G-F, Fowler JS. 2002b. 'Nonhedonic' food motivation in humans involves dopamine in the dorsal striatum and methylphenidate amplifies this. Synapse 44: 175-180.
157. Volkow ND, Wang G-J, Fowler JS, et al. 2002a. Relationship between blockade of dopamine transporters by oral methylphenidate and the increases in extracellular dopamine: therapeutic implication. Synapse 43: 181-187.
158. Wagner MW, Markowitz JS, Patrick KS. 2001. Methylphenidate ER lodging in esophagus. J Am Acad Child Adolesc Psychiatry 40: 1244-1245.
159. Weiss M, Hechtman L, Turay A, et al. 2007. Once-daily multilayer-release methylphenidate in a double-blind, crossover comparison to immediaterelease methylphenidate in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 17: 675-688.
160. Wigal S, Swanson JM, Feifel D, et al. 2004. A double-blind, placebocontrolled trial of dexmethylphenidate hydrochloride and d,l-threomethylphenidate hydrochloride in chidren with attention deficit-hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 43: 1406-1414.
161. Wilens TE, Adler LA, Adams J, et al. 2008a. Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. J Am Acad Child Adolesc Psychiatry 47: 21-31.
162. Wilens T, Boellner SW, Lopez FA, et al. 2008b. Varying the wear time of the methylphenidate transdermal system in children with attention-deficit- hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 47: 700-708.
163. Williard RL, Middaugh LD, Zhu H, Patrick KS. 2007. Methylphenidate and its ethanol transesterification metabolite ethylphenidate: brain disposition, monoamine transporters and motor activity. Behav Pharmacol 18: 39-52.
164. Yang PB, Swann AC, Dafny N. 2007. Chronic administration of methylphenidate produces neurophysiological and behavioral sensitization. Brian Res 1145: 66-80.
165. Zabik JE, Levine RM, Maikel RP. 1978. Drug interactions with brain biogenic amines and the effects of amphetamine isomers on locomotor activity. Pharmacol Biochem Behav 8: 429-435.
166. Zhu H-J, Patrick KS, Yuan H-J, et al. 2008. Two CES1 gene mutations lead to dysfunctional carboxylesterase-1 activity in man: clinical significance and molecular basis. Am J Hum Genet 82: 1-8.